ReNerve

## ASX Announcement

17 September 2025

The Manager
Market Announcements Platform
Australian Securities Exchange Limited

### NOTICE UNDER SECTION 708A(5)(e) OF THE CORPORATIONS ACT 2001 (CTH)

This notice is given by ReNerve Limited (ASX:RNV) (ReNerve or the Company) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (the Act).

ReNerve has issued 600,000 fully paid ordinary shares (New Shares) at an issue price of $0.10 per New Share pursuant to the Appendix 2A announced to ASX on 17 September 2025.

For the purpose of section 708A(6) of the Act, the Company hereby notifies that:

a) the Company issued the New Shares without disclosure to investors under Part 6D.2 of the Act;
b) this notice is given under section 708A(5)(e) of the Act;
c) as at the date of this notice, the Company has complied with:
    (i) the provisions of Chapter 2M of the Act as they apply to the Company; and
    (ii) sections 674 of the Act;
d) as at the date of this notice, there is no information that is 'excluded information' of the type referred to in section 708A(7) or section 708A(8) of the Act that is required to be disclosed pursuant to section 708A(6)(e) of the Act.

**This announcement has been approved for release by the Company's Board of Directors.**

**- ENDS -**

**For further information and enquiries, please contact:**

**Dr Julian Chick**
CEO & Managing Director
ReNerve Ltd
+61 (03) 9482 3940
info@renerve.com.au

## About ReNerve Limited (ASX:RNV)

**ReNerve Limited (ASX:RNV) aims to transform nerve repair and improve lives through breakthrough medical technology.** Founded by a neurosurgeon and MedTech researchers, ReNerve is a rapidly growing medical device company that aims to revolutionise peripheral nerve surgery with it innovative, ready-to-use solutions for peripheral nerve injury repairs (PNI).

**Proven Clinical Success**

A clinical study announced in March 2025 has demonstrated remarkable results, showing that patients treated with the NervAlign® Nerve Cuff experienced post-surgical pain scores dropping from 7.1 to just 0.4, compared to from 7.1 to 3.3 without the device being used – a statistically significant improvement for patients.

**Comprehensive Product Portfolio**

ReNerve is advancing a complete suite of nerve repair solutions:

- **NervAlign® Nerve Cuff** – Our bioabsorbable protective wrap, naturally absorbed within six months of surgery.
- **Deep Dermal tissue product --** A deep dermal product used in the repair of reconstructive and cosmetic surgical cases.
- **Amniotic tissue product ranges --** Three amniotic tissue product ranges used to aid the healing of wounds.
- **NervAlign® Nerve Conduit Range –** Next-generation nerve conduit leveraging advantages of eCOO technology and designed to facilitate nerve growth over short gaps between nerve ends.
- **NervAlign® Nerve Guide Matrix** – Focused on the nerve graft market for treating more severe nerve injuries, but eliminating the need for patients to undergo additional sural nerve harvesting.
- **NervAlign® Bionic Nerve** – Next-generation combination technology for the most challenging nerve repairs.

**Growth**

With demonstrated market traction since the Company's 2022 product launch, ReNerve achieved 53% revenue growth in FY25, reaching $271k in sales. Our high-margin products are providing solutions for surgeons seeking superior patient outcomes in the rapidly expanding global nerve repair market, valued at US$1.96 billion in 2024 and is projected to reach $6.2 billion by 2031.[1]

[1] Global Nerve Repair Biomaterials Market Research Report (2020 – 2031)

**Vision and Values**

We're not just developing medical devices – we're engineering hope. By creating the ideal healing environment for nerve repair and regeneration, ReNerve bridges critical gaps in healthcare while empowering the human body's natural healing process. Our cleaner, safer, and more effective solutions represent the future of peripheral nerve surgery.